Orgenesis Inc. (ORGS)

NASDAQ: ORGS · IEX Real-Time Price · USD
0.600
-0.029 (-4.59%)
At close: Feb 27, 2024, 4:00 PM
0.594
-0.007 (-1.10%)
After-hours: Feb 27, 2024, 6:21 PM EST
-4.59%
Market Cap 20.08M
Revenue (ttm) 27.75M
Net Income (ttm) -25.07M
Shares Out 31.88M
EPS (ttm) 0.90
PE Ratio 0.67
Forward PE 1.11
Dividend n/a
Ex-Dividend Date n/a
Volume 45,430
Open 0.620
Previous Close 0.629
Day's Range 0.570 - 0.625
52-Week Range 0.250 - 1.600
Beta 0.81
Analysts Buy
Price Target 6.00 (+899.83%)
Earnings Date Mar 19, 2024

About ORGS

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care f... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 167
Stock Exchange NASDAQ
Ticker Symbol ORGS
Full Company Profile

Financial Performance

In 2022, Orgenesis's revenue was $36.03 million, an increase of 1.47% compared to the previous year's $35.50 million. Losses were -$14.89 million, -17.53% less than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for ORGS stock is "Buy" and the 12-month stock price forecast is $6.0.

Price Target
$6.0
(899.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has...

27 days ago - GlobeNewsWire

Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM

GERMANTOWN, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapi...

3 months ago - GlobeNewsWire

Orgenesis Provides Business Update for the Third Quarter of 2023

GERMANTOWN, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc.

3 months ago - GlobeNewsWire

Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering

GERMANTOWN, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (“Orgenesis”) (Nasdaq: ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), announc...

3 months ago - GlobeNewsWire

Orgenesis Announces Withdrawal of Proposed Public Offering

GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapi...

4 months ago - GlobeNewsWire

Orgenesis Announces Proposed Underwritten Public Offering

GERMANTOWN, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapi...

4 months ago - GlobeNewsWire

Orgenesis Provides Business Update for Second Quarter of 2023

Reports Progress in Advancing the Rollout of the POCare Platform  and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) ...

7 months ago - GlobeNewsWire

Orgenesis Schedules Second Quarter 2023 Business Update Conference Call

GERMANTOWN, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapi...

7 months ago - GlobeNewsWire

Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapi...

8 months ago - GlobeNewsWire

Orgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout California

GERMANTOWN, Md. and DAVIS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell...

9 months ago - GlobeNewsWire

Claudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of Orgenesis

GERMANTOWN, Md., May 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

9 months ago - GlobeNewsWire

Orgenesis Academy Graduates First Class of Cell and Gene Therapy Experts from theraCell Laboratories-backed Master's Program

Program prepares scientists to meet the accelerating demand for cell and gene therapy expertise across an industry already delivering cures for dangerous diseases Program prepares scientists to meet t...

10 months ago - GlobeNewsWire

Orgenesis to Participate in Benchmark's 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023

GERMANTOWN, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

10 months ago - GlobeNewsWire

Orgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors

GERMANTOWN, Md. and PRAGUE, Czech Republic, May 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ORGS) (“Orgenesis”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT...

10 months ago - GlobeNewsWire

Orgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare Strategy

GERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

10 months ago - GlobeNewsWire

Orgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service Subsidiary

GERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

10 months ago - GlobeNewsWire

Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022

Rapid g rowth r eflect s p rogress of POCare Platform

1 year ago - GlobeNewsWire

Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call

GERMANTOWN, Md., March 17, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therap...

1 year ago - GlobeNewsWire

Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California

GERMANTOWN, Md., March 16, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapi...

1 year ago - GlobeNewsWire

Orgenesis Inc. Announces Closing of $3.7 Million Registered Direct Offering

GERMANTOWN, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Orgenesis, Inc. (Nasdaq: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapi...

1 year ago - GlobeNewsWire

Orgenesis Inc. Announces Pricing of $3.7 Million Registered Direct Offering

GERMANTOWN, Md., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Orgenesis, Inc. (Nasdaq: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapi...

1 year ago - GlobeNewsWire

Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022

Secures up to $50 Million of Funding from Metalmark Capital Partners  Expected to Accelerate Rollout of Point-of-Care Services

1 year ago - GlobeNewsWire

Orgenesis Schedules Third Quarter 2022 Business Update Conference Call

GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapi...

1 year ago - GlobeNewsWire

Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services

GERMANTOWN, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapi...

1 year ago - GlobeNewsWire

Orgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022

Secures Funding from Metalmark Capital Partners to Drive Growth

1 year ago - GlobeNewsWire